Table 1.
n (%) | ||||
---|---|---|---|---|
Cases N = 14 |
Controls N = 290 |
|||
Recruitment source | ||||
PACE† | 5 (35.7) | 274 (94.5) | ||
Geisinger Health System | 9 (64.3) | 16 ( 5.5) | ||
Sex | ||||
Male | 4 (28.6) | 79 (27.2) | ||
Female | 10 (71.4) | 211 (72.8) | ||
Race | ||||
White | 14 (100) | 274 (94.5) | ||
African American | 0 ( 0.0) | 13 ( 4.5) | ||
Other | 0 ( 0.0) | 2 ( 0.7) | ||
Unknown | 0 ( 0.0) | 1 ( 0.3) | ||
Median age, in years (interquartile range) |
68.4 (33.9) | 76.3 (10.2) | ||
Mean phenytoin concentration on admission‡, mg/L (standard deviation) |
31.2 (12.9) | - | ||
Crude OR (95% CI) |
Adjusted§ OR (95% CI) |
|||
Genotype | ||||
CYP2C9 | ||||
*1/*1 | 8 (57.1) | 194 (66.9) | 1.00 (reference) | 1.00 (reference) |
*1/*2 | 4 (28.6) | 89 (30.7) | 1.09 (0.32–3.71) | 0.96 (0.25–3.66) |
*1/*3 | 1 (7.15) | 4 ( 1.4) | 6.06 (0.61–60.6) | 8.91 (0.79–100) |
*2/*2 | 1 (7.15) | 3 ( 1.0) | 8.08 (0.75–86.6) | 9.48 (0.79–115) |
*2/*3 | 0 ( 0.0) | 0 ( 0.0) | - | - |
*3/*3 | 0 ( 0.0) | 0 ( 0.0) | - | - |
CYP2C19 | ||||
*1/*1 | 10 (71.4) | 213 (73.5) | 1.00 (reference) | 1.00 (reference) |
*1/*2 | 2 (14.3) | 70 (24.1) | 0.61 (0.13–2.84) | 0.50 (0.09–2.73) |
*1/*3 | 2 (14.3) | 7 ( 2.4) | 6.09 (1.12–33.1) | 4.21 (0.58–30.8) |
*2/*2 | 0 ( 0.0) | 0 ( 0.0) | - | - |
*2/*3 | 0 ( 0.0) | 0 ( 0.0) | - | - |
*3/*3 | 0 ( 0.0) | 0 ( 0.0) | - | - |
ABCB1 | ||||
C/C | 3 (21.4) | 72 (24.8) | 1.00 (reference) | 1.00 (reference) |
C/T | 6 (42.9) | 123 (42.4) | 1.17 (0.28–4.82) | 0.84 (0.18–3.81) |
T/T | 5 (35.7) | 95 (32.8) | 1.26 (0.29–5.46) | 1.32 (0.28–6.18) |
Pennsylvania Pharmaceutical Assistance Contract for the Elderly prescription drug program (including members of the Needs Enhancement Tier)
Usual therapeutic range = 10 to 20 mg/L
Adjusted for age, sex, and number of variant alleles of other metabolic enzymes
OR = odds ratio; CI = confidence interval